However, taking EGFR expression levels/mutations into consideration could improve clinical outcomes, as in vitro and in vivo studies showed an anti-tumor effect of erlotinib only in EGFR high level, although not low level endometrial cancer cells [108]. This evidence concerns the gene EGFR and endometrial cancer.